Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors

BACKGROUND: Chiauranib is a novel orally active multi-target inhibitor that simultaneously inhibits the angiogenesis-related kinases (VEGFR2, VEGFR1, VEGFR3, PDGFRα, and c-Kit), mitosis-related kinase Aurora B, and chronic inflammation-related kinase CSF-1R. This phase I dose-escalation study was to...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Yongkun, Yang, Lin, Hao, Xuezhi, Liu, Yutao, Zhang, Jinwen, Ning, Zhiqiang, Shi, Yuankai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6332596/
https://www.ncbi.nlm.nih.gov/pubmed/30642372
http://dx.doi.org/10.1186/s13045-018-0695-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6332596/
https://www.ncbi.nlm.nih.gov/pubmed/30642372
http://dx.doi.org/10.1186/s13045-018-0695-0

Ejemplares similares